data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
Watch
YouTube
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
AEterna Zentaris
(NASDAQ:AEZS)
Aeterna Zentaris Inc. - Common Stock recently split on Thursday, July 21, 2022 with a ratio of 1:25
$4.97
Last update: 3:28PM
Day High/Low4.81 - 5.03
52 Week High/Low0.16 - 5.9
Open / Close4.85 / -
Float / Outstanding4.9M / 4.9M
Vol / Avg.60.1K / 1.2M
Mkt Cap24.1M
P/E-
50d Avg. Price1.28
Div / Yield-
Payout Ratio-
EPS-0.87
Total Float4.9M

AEterna Zentaris (NASDAQ:AEZS), Quotes and News Summary

AEterna Zentaris (NASDAQ: AEZS)

Day High/Low4.81 - 5.03
52 Week High/Low0.16 - 5.9
Open / Close4.85 / -
Float / Outstanding4.9M / 4.9M
Vol / Avg.60.1K / 1.2M
Mkt Cap24.1M
P/E-
50d Avg. Price1.28
Div / Yield-
Payout Ratio-
EPS-0.87
Total Float4.9M
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.
Read More

Earnings

see more
Q3 2022Est.ActualSurprise
EPS
(EXPECTED)2022-11-03
REV
Q2 2022Est.ActualSurprise
EPS-0.680-0.870 -0.1900
REV1.310M-222.000K-1.532M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

AEterna Zentaris Questions & Answers

Q
How do I buy AEterna Zentaris (AEZS) stock?
A

You can purchase shares of AEterna Zentaris (NASDAQ: AEZS) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are AEterna Zentaris's (AEZS) competitors?
A

There are no as such competitors for AEterna Zentaris.

Q
What is the target price for AEterna Zentaris (AEZS) stock?
A

The latest price target for AEterna Zentaris (NASDAQ: AEZS) was reported by HC Wainwright & Co. on Wednesday, March 30, 2022. The analyst firm set a price target for 1.50 expecting AEZS to fall to within 12 months (a possible -69.82% downside). 2 analyst firms have reported ratings in the last year.

Q
Current Stock Price for AEterna Zentaris (AEZS)?
A

The stock price for AEterna Zentaris (NASDAQ: AEZS) is $4.97 last updated Today at August 8, 2022, 7:28 PM UTC.

Q
Does AEterna Zentaris (AEZS) pay a dividend?
A

There are no upcoming dividends for AEterna Zentaris.

Q
When is AEterna Zentaris (NASDAQ:AEZS) reporting earnings?
A

AEterna Zentaris’s Q3 earnings are confirmed for Thursday, November 3, 2022.

Q
Is AEterna Zentaris (AEZS) going to split?
A

There is no upcoming split for AEterna Zentaris.

Q
What sector and industry does AEterna Zentaris (AEZS) operate in?
A

AEterna Zentaris is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.